• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

凝血因子V:一颗旧星再度闪耀。

Coagulation factor V: an old star shines again.

作者信息

Rosing J, Tans G

机构信息

Department of Biochemistry, Maastricht University, The Netherlands.

出版信息

Thromb Haemost. 1997 Jul;78(1):427-33.

PMID:9198191
Abstract

Blood coagulation factor V plays an important role in the regulation of thrombin formation. Activation of factor V by traces of activated coagulation factors (thrombin, factor Xa or meizothrombin) yields factor Va, the non-enzymatic cofactor of the prothrombinase complex. Since factor Va accelerates prothrombin activation under physiological conditions more than 10(4)-fold it is not surprising that down-regulation of factor Va cofactor activity by the protein C pathway is a very effective way for maintaining the hemostatic balance. In this paper we have reviewed the present status of structural knowledge of factor V and Va, the molecular changes in factor V that occur during factor V activation, the function of factor Va in prothrombin activation and the molecular mechanism of inactivation of factor Va by APC. Although considerable insight in the structure-function relationship of factor V and Va has been achieved, the study of mutated factor V molecules obtained by recombinant DNA technology will undoubtedly resolve remaining questions. The latter is illustrated by the fact that the discovery of factor VaLeiden has significantly contributed to our present knowledge on the regulation of the cofactor activity of factor Va via the protein C pathway. It appears that modulation of the activity of APC by protein S and factor Xa will strongly affect the in vivo activity of this pathway. Factor V not only plays an important role in the regulation of the activity of the prothrombinase complex but also acts as cofactor in APC-mediated inactivation of factor VIIIa. This gives rise to a rather intricate mechanism of regulation of thrombin formation by APC that thus far has been mainly studied in model systems containing purified proteins. Thus, extensive studies in plasma will be required in order to get more insight in the in vivo regulation of thrombin formation via the protein C pathway.

摘要

血液凝固因子V在凝血酶形成的调节中起重要作用。痕量活化凝血因子(凝血酶、因子Xa或中间凝血酶)激活因子V产生因子Va,即凝血酶原酶复合物的非酶辅因子。由于因子Va在生理条件下加速凝血酶原激活的作用超过10^4倍,因此蛋白C途径下调因子Va辅因子活性是维持止血平衡的一种非常有效的方式也就不足为奇了。在本文中,我们综述了因子V和Va的结构知识现状、因子V激活过程中发生的分子变化、因子Va在凝血酶原激活中的功能以及活化蛋白C(APC)使因子Va失活的分子机制。尽管对因子V和Va的结构-功能关系已经有了相当深入的了解,但通过重组DNA技术获得的突变因子V分子的研究无疑将解决剩余的问题。因子VaLeiden的发现对我们目前关于通过蛋白C途径调节因子Va辅因子活性的认识有显著贡献,这一事实就说明了后者。似乎蛋白S和因子Xa对APC活性的调节将强烈影响该途径的体内活性。因子V不仅在凝血酶原酶复合物活性的调节中起重要作用,而且在APC介导的因子VIIIa失活中作为辅因子发挥作用。这导致了APC调节凝血酶形成的机制相当复杂,迄今为止主要在含有纯化蛋白质的模型系统中进行研究。因此,需要在血浆中进行广泛研究,以便更深入地了解通过蛋白C途径对凝血酶形成的体内调节。

相似文献

1
Coagulation factor V: an old star shines again.凝血因子V:一颗旧星再度闪耀。
Thromb Haemost. 1997 Jul;78(1):427-33.
2
Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.活化蛋白C对凝血酶形成的调节:因子V莱顿突变的影响。
Semin Hematol. 1997 Jul;34(3):244-55.
3
Factor V and protein S as cofactors to activated protein C.因子V和蛋白S作为活化蛋白C的辅助因子。
Haematologica. 1997 Jan-Feb;82(1):91-5.
4
Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding.组织蛋白酶G和弹性蛋白酶对因子V的蛋白水解作用表明,在精氨酸1545处的切割通过促进因子Xa的结合来优化辅因子功能。
Biochemistry. 1998 Aug 25;37(34):11896-906. doi: 10.1021/bi980520v.
5
A prothrombinase-based assay for detection of resistance to activated protein C.一种基于凝血酶原酶的检测活化蛋白C抵抗性的检测方法。
Thromb Haemost. 1996 Sep;76(3):404-10.
6
Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation.因子V增强蛋白S在活化蛋白C介导的因子VIII失活中的辅因子功能:因子V R506Q突变的影响
Thromb Haemost. 1996 Aug;76(2):208-14.
7
Bothrojaracin, a proexosite I ligand, inhibits factor Va-accelerated prothrombin activation.Bothrojaracin,一种外显子I配体,可抑制因子Va加速的凝血酶原激活。
Thromb Haemost. 2002 Feb;87(2):288-93.
8
Completed three-dimensional model of human coagulation factor va. Molecular dynamics simulations and structural analyses.人凝血因子Va的完整三维模型。分子动力学模拟与结构分析。
Biochemistry. 2005 Oct 4;44(39):13082-90. doi: 10.1021/bi050891t.
9
Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways.人因子Va1和因子Va2:在凝血和抗凝途径中的特性。
Biochemistry. 1997 Mar 18;36(11):3331-5. doi: 10.1021/bi9623284.
10
Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor VIIIa - factor IXa complex -- species specific interactions of components of the protein C anticoagulant system.在因子VIIIa - 因子IXa复合物失活过程中,因子V和蛋白S对活化蛋白C的协同辅助因子功能——蛋白C抗凝系统各组分的种属特异性相互作用
Thromb Haemost. 1997 Sep;78(3):1030-6.

引用本文的文献

1
Cryo-EM structure of coagulation factor V short.凝血因子 V 短链的冷冻电镜结构。
Blood. 2023 Jun 29;141(26):3215-3225. doi: 10.1182/blood.2022019486.
2
Impaired factor V-related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations.存在 A2086D 和 W1920R 突变导致的因子 V 相关抗凝机制受损和深静脉血栓形成。
Blood Adv. 2023 Jun 27;7(12):2831-2842. doi: 10.1182/bloodadvances.2022008918.
3
Cryo-EM structures of coagulation factors.凝血因子的冷冻电镜结构
Res Pract Thromb Haemost. 2022 Nov 2;6(7):e12830. doi: 10.1002/rth2.12830. eCollection 2022 Oct.
4
A Novel Phenotype of the Factor 5 Gene Mutation (Homozygote Met1736Val and Heterozygote Asp68His) Is Associated With Moderate Factor V Deficiency.因子Ⅴ基因突变(纯合子Met1736Val和杂合子Asp68His)的一种新表型与中度因子Ⅴ缺乏相关。
Front Med (Lausanne). 2022 Jun 9;9:870269. doi: 10.3389/fmed.2022.870269. eCollection 2022.
5
Integrative analyses of genes related to femoral head osteonecrosis: an umbrella review of systematic reviews and meta-analyses of observational studies.整合分析与股骨头坏死相关的基因:观察性研究系统评价和荟萃分析的伞状综述。
J Orthop Surg Res. 2022 Mar 28;17(1):182. doi: 10.1186/s13018-022-03079-4.
6
Cryo-EM structures of human coagulation factors V and Va.人凝血因子 V 和 Va 的冷冻电镜结构。
Blood. 2021 Jun 3;137(22):3137-3144. doi: 10.1182/blood.2021010684.
7
G2691A and C2491T mutations of factor V gene and pre-disposition to myocardial infarction in Morocco.摩洛哥人群中凝血因子V基因的G2691A和C2491T突变与心肌梗死易感性
Biomed Rep. 2016 Nov;5(5):618-622. doi: 10.3892/br.2016.768. Epub 2016 Sep 30.
8
Meta-analysis of Factor V Leiden G1691A polymorphism and osteonecrosis of femoral head susceptibility.凝血因子V Leiden基因G1691A多态性与股骨头坏死易感性的Meta分析。
Biomed Rep. 2013 Jul;1(4):594-598. doi: 10.3892/br.2013.93. Epub 2013 Apr 9.
9
Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway.蛋白 C 通路的抗凝和细胞保护作用机制。
J Thromb Haemost. 2013 Jun;11 Suppl 1(0 1):242-53. doi: 10.1111/jth.12247.
10
First study of the C2491t nonsense mutation frequency in moroccan healthy population.摩洛哥健康人群中 C2491t 无义突变频率的首次研究。
J Mol Neurosci. 2013 Oct;51(2):425-7. doi: 10.1007/s12031-013-0045-1. Epub 2013 Jun 15.